{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:00:38Z","timestamp":1790708438976,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017478","name":"Usona Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Mental Health Res"],"DOI":"10.1038\/s44184-024-00095-6","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:47:57Z","timestamp":1738900077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A qualitative analysis of the psychedelic mushroom come-up and come-down"],"prefix":"10.1038","volume":"4","author":[{"given":"Ari","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earth","family":"Erowid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fire","family":"Erowid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Raison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"95_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KA Andersen","year":"2021","unstructured":"Andersen, K. A. et al. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern\u2010era clinical studies. Acta Psychiatr. Scand. 143, 101\u2013118 (2021).","journal-title":"Acta Psychiatr. Scand."},{"key":"95_CR2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8, 974 (2018).","journal-title":"Front. Pharmacol."},{"key":"95_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2020","unstructured":"Yaden, D. B. & Griffiths, R. R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 4, 568\u2013572 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"95_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2020","unstructured":"Olson, D. E. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 4, 563\u2013567 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"95_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268\u2013283 (2006).","journal-title":"Psychopharmacology"},{"key":"95_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths, R. R. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 22, 621\u2013632 (2008).","journal-title":"J. Psychopharmacol."},{"key":"95_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths, R. R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218, 649\u2013665 (2011).","journal-title":"Psychopharmacology"},{"key":"95_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0269881120967878","volume":"35","author":"AK Davis","year":"2021","unstructured":"Davis, A. K. et al. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. J. Psychopharmacol. 35, 437\u2013446 (2021).","journal-title":"J. Psychopharmacol."},{"key":"95_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman, L. et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J. Psychopharmacol. 33, 1076\u20131087 (2019).","journal-title":"J. Psychopharmacol."},{"key":"95_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/0269881120959637","volume":"35","author":"A Brouwer","year":"2021","unstructured":"Brouwer, A. & Carhart-Harris, R. L. Pivotal mental states. J. Psychopharmacol. 35, 319\u2013352 (2021).","journal-title":"J. Psychopharmacol."},{"key":"95_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.1217","volume":"12","author":"A Brouwer","year":"2024","unstructured":"Brouwer, A., Carhart-Harris, R. L. & Raison, C. L. Psychotomimetic compensation versus sensitization. Pharmacol. Res. Perspect. 12, 1\u201316 (2024).","journal-title":"Pharmacol. Res. Perspect."},{"key":"95_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Nutt, D. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091\u20131120 (2017).","journal-title":"J. Psychopharmacol."},{"key":"95_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/FBP.0000000000000459","volume":"30","author":"KS Murnane","year":"2019","unstructured":"Murnane, K. S. Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder. Behav. Pharmacol. 30, 151 (2019).","journal-title":"Behav. Pharmacol."},{"key":"95_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/wps.20959","volume":"21","author":"P Fusar\u2010Poli","year":"2022","unstructured":"Fusar\u2010Poli, P. et al. The lived experience of psychosis: a bottom\u2010up review co\u2010written by experts by experience and academics. World Psychiatry 21, 168\u2013188 (2022).","journal-title":"World Psychiatry"},{"key":"95_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1524838020933844","volume":"23","author":"S Geoffrion","year":"2022","unstructured":"Geoffrion, S. et al. Systematic review and meta-analysis on acute stress disorder: rates following different types of traumatic events. Trauma Viol. Abus. 23, 213\u2013223 (2022).","journal-title":"Trauma Viol. Abus."},{"key":"95_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/schbul\/22.2.353","volume":"22","author":"AR Yung","year":"1996","unstructured":"Yung, A. R. & McGorry, P. D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22, 353\u2013370 (1996).","journal-title":"Schizophr. Bull."},{"key":"95_CR17","unstructured":"Hardy, A. The spiritual nature of man: A study of contemporary religious experience. Oxford University Press (1979)."},{"key":"95_CR18","doi-asserted-by":"crossref","unstructured":"Yaden, D. B. & Newberg, A. The varieties of spiritual experience: 21st century research and perspectives. Oxford University Press (2022).","DOI":"10.1093\/oso\/9780190665678.001.0001"},{"key":"95_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","volume":"36","author":"JM Peill","year":"2022","unstructured":"Peill, J. M. et al. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36, 31\u201355 (2022).","journal-title":"J. Psychopharmacol."},{"key":"95_CR20","doi-asserted-by":"crossref","unstructured":"Eatough, V. & Smith, J. A. Interpretative phenomenological analysis. In (eds.) Harper D and Thompson AR The Sage handbook of qualitative research in psychology, 193-209 (2017).","DOI":"10.4135\/9781526405555.n12"},{"key":"95_CR21","first-page":"1","volume":"3","author":"R Anderson","year":"2007","unstructured":"Anderson, R. Thematic content analysis (TCA). Descr. Present. Qual. Data 3, 1\u20134 (2007).","journal-title":"Descr. Present. Qual. Data"},{"key":"95_CR22","unstructured":"bongd81. Depth and Intensity of It Took Me by Surprise: An Experience with Mushrooms - P. mexicana (sclerotia) (exp114653). Erowid.org. Aug 20, 2020. erowid.org\/exp\/114653."},{"key":"95_CR23","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders (5th ed, text rev). https:\/\/doi.org\/10.1176\/appi.books.9780890425787","DOI":"10.1176\/appi.books.9780890425787"},{"key":"95_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-019-0228-0","volume":"15","author":"G Russell","year":"2019","unstructured":"Russell, G. & Lightman, S. The human stress response. Nat. Rev. Endocrinol. 15, 525\u2013534 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"95_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0006-3223(02)01335-5","volume":"51","author":"AY Shalev","year":"2002","unstructured":"Shalev, A. Y. Acute stress reactions in adults. Biol. Psychiatry 51, 532\u2013543 (2002).","journal-title":"Biol. Psychiatry"},{"key":"95_CR26","unstructured":"World Health Organization (2019) International statistical classification of diseases and related health problems (11th ed.). https:\/\/icd.who.int\/."},{"key":"95_CR27","doi-asserted-by":"crossref","unstructured":"Jones, N. T. et al. Delayed Anxiolytic-Like Effects of Psilocybin in Male Mice Are Supported by Acute Glucocorticoid Release. bioRxiv: 2020-08 (2020).","DOI":"10.1101\/2020.08.12.248229"},{"key":"95_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1091\/mbc.E20-05-0340","volume":"32","author":"MI Banks","year":"2021","unstructured":"Banks, M. I. et al. Catalysts for change: the cellular neurobiology of psychedelics. Mol. Biol. Cell 32, 1135\u20131144 (2021).","journal-title":"Mol. Biol. Cell"},{"key":"95_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41386-023-01642-z","volume":"48","author":"H De Wit","year":"2023","unstructured":"De Wit, H., Heilig, M. & Bershad, A. K. Does acute stress play a role in the lasting therapeutic effects of psychedelic drugs? Neuropsychopharmacology 48, 1422\u20131424 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"95_CR30","unstructured":"S. \u201cValidated in the Ocean of Love: An Experience with Mushrooms - P. cubensis (exp113944)\u201d. Erowid.org. Feb 9, 2020. erowid.org\/exp\/113944"},{"key":"95_CR31","doi-asserted-by":"publisher","unstructured":"Passie, T., Guss, J. & Kr\u00e4henmann, R. (2022) Lower-dose psycholytic therapy\u2013a neglected approach. Front. Psychiatry 13: https:\/\/doi.org\/10.3389\/fpsyt.2022.1020505","DOI":"10.3389\/fpsyt.2022.1020505"},{"key":"95_CR32","doi-asserted-by":"publisher","first-page":"35561","DOI":"10.4088\/PCC.20m02747","volume":"23","author":"K Anagha","year":"2021","unstructured":"Anagha, K., Shihabudheen, P. & Uvais, N. Side effect profiles of selective serotonin reuptake inhibitors: a cross-sectional study in a naturalistic setting. Prim. Care Companion CNS Disord. 23, 35561 (2021).","journal-title":"Prim. Care Companion CNS Disord."},{"key":"95_CR33","first-page":"22","volume":"3","author":"JM Ferguson","year":"2001","unstructured":"Ferguson, J. M. SSRI antidepressant medications: adverse effects and tolerability. Prim. Care Companion J. Clin. Psychiatry 3, 22 (2001).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"95_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0269881120986422","volume":"35","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos, R. G. et al. Hallucinogenic\/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. J. Psychopharmacol. 35, 453\u2013458 (2021).","journal-title":"J. Psychopharmacol."},{"key":"95_CR35","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.pharep.2019.05.012","volume":"71","author":"D Gawli\u0144ski","year":"2019","unstructured":"Gawli\u0144ski, D. et al. Adaptive mechanisms following antidepressant drugs: focus on serotonin 5-HT2A receptors. Pharmacol. Rep. 71, 994\u20131000 (2019).","journal-title":"Pharmacol. Rep."},{"key":"95_CR36","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval, N. R. et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int. J. Mol. Sci. 22, 835 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"95_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1515\/humor-2019-0015","volume":"33","author":"DA Granitsas","year":"2020","unstructured":"Granitsas, D. A. All laughter is nervous: An anxiety-based understanding of incongruous humor. Humor 33, 625\u2013643 (2020).","journal-title":"Humor"},{"key":"95_CR38","unstructured":"Safron, A. (2019) Rapid Anxiety Reduction (RAR): A unified theory of humor. arXiv:1911.02364."},{"key":"95_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0306-9877(98)90061-5","volume":"51","author":"VS Ramachandran","year":"1998","unstructured":"Ramachandran, V. S. The neurology and evolution of humor, laughter, and smiling: the false alarm theory. Med. Hypotheses 51, 351\u2013354 (1998).","journal-title":"Med. Hypotheses"},{"key":"95_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuropharm.2018.03.010","volume":"142","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. The entropic brain-revisited. Neuropharmacology 142, 167\u2013178 (2018).","journal-title":"Neuropharmacology"},{"key":"95_CR41","doi-asserted-by":"publisher","unstructured":"Carhart-Harris, R. L. et al. (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front. Human Neurosci. 20. https:\/\/doi.org\/10.3389\/fnhum.2014.00020","DOI":"10.3389\/fnhum.2014.00020"},{"key":"95_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol. Rev. 71, 316\u2013344 (2019).","journal-title":"Pharmacol. Rev."},{"key":"95_CR43","unstructured":"Hofmann, A. (1979\/2013) LSD: my problem child. Oxford University Press."},{"key":"95_CR44","first-page":"1","volume":"239","author":"J Kuc","year":"2021","unstructured":"Kuc, J. et al. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology 239, 1\u201316 (2021).","journal-title":"Psychopharmacology"},{"key":"95_CR45","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"95_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881120959609","volume":"35","author":"DS Stenb\u00e6k","year":"2021","unstructured":"Stenb\u00e6k, D. S. et al. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J. Psychopharmacol. 35, 459\u2013468 (2021).","journal-title":"J. Psychopharmacol."}],"container-title":["npj Mental Health Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44184-024-00095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-024-00095-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44184-024-00095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:48:08Z","timestamp":1738900088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44184-024-00095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1038\/s44184-024-00095-6","relation":{},"ISSN":["2731-4251"],"issn-type":[{"value":"2731-4251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB reports receiving an academic scholarship from Usona Institute. CLR reports consulting work for Usona Institute and Novartis. EE, FE, and ST are employees of Erowid Center, a US 501(c)(3) non-profit educational organization, though they receive no bonuses or additional compensation for work related to this topic. Funding was provided to CLR via the Mary Sue and Mike Shannon Distinguished Chair for Healthy Minds, Children and Families and to AB via an academic scholarship from Usona Institute. The funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}